"This study was an investigator initiated study, and what they wanted to do was a randomized trial for large prostates, so 80 to 180 grams, between Aquablation and prostate enucleation," says Naeem ...

"We see the overall survival, whether it is [in] all-comers, in HRR gene mutation-positive patients, or in HRR gene [mutation]-negative patients or [those] who did not have mutations, the overall ...

Experts discuss how they communicate various treatment options for non–muscle-invasive bladder cancer (NMIBC) with patients and health care professionals.

ProACT is recommended for non-radiated patients with stress urinary incontinence, offering adjustability for mild to severe cases. The procedure combines cystoscopy and fluoroscopy, with postoperative ...

Experts share their initial impressions of the available data on immunotherapies, including PD-L1 inhibitors durvalumab and sasanlimab, being evaluated in bacille Calmette-Guérin (BCG)–unresponsive ...

Sixty percent of patients with baseline UUI experienced complete resolution at one year post-surgery, independent of sling type. De novo UUI was observed in 11% of patients, with colpocleisis ...

"This is another tool in our armamentarium to treat muscle-invasive bladder cancer and represents an advance compared to where we've been over the past few decades," says Matthew D. Galsky, MD. The ...

High interreader and intrareader agreement rates were found, especially in newly diagnosed prostate cancer patients, supporting 18F-Flotufolastat's FDA approval. Lower agreement rates in the ...

"They are risking their own lives for their job, so it's the part of the whole community to do our best to try to keep them safe," says Sima P. Porten, MD, MPH. Firefighters face an increased risk of ...

Pembrolizumab and lenvatinib showed clinical activity in locally advanced, non-metastatic clear cell RCC, with a median tumor reduction of 22%. The combination had a manageable safety profile, with ...

“If it is as efficacious as it looks, we will have more patients who are getting effective standard of care treatment, not needing to go on to further treatment, not having recurrences, [having ...

"We demonstrate that patients with metastatic disease stayed on therapy longer—a median of 9 months vs 7 months for the non-metastatic patients," says Rana R. McKay, MD, FASCO. Overall, data from the ...